The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single-arm phase II trial versusĀ a consecutive single-center collective of ovarian cancer patients without immunotherapy.
Klaus Pietzner
Honoraria - Fresenius Biotech
Radoslav Chekerov
No relevant relationships to disclose
Alexander Reinthaller
No relevant relationships to disclose
Daniel Reimer
No relevant relationships to disclose
Toralf Reimer
No relevant relationships to disclose
Lukas Angleitner-Boubenizek
No relevant relationships to disclose
Miriam Tschirschmann
Employment or Leadership Position - Fresenius Biotech
Horst Lindhofer
Employment or Leadership Position - TRION Research
Stock Ownership - TRION Research
Elena Ioana Braicu
No relevant relationships to disclose
Christina Fotopoulou
No relevant relationships to disclose
Jalid Sehouli
No relevant relationships to disclose